当前位置: 首页 >> 检索结果
21. Stroke Prevention With Prophylactic Left Atrial Appendage Occlusion in Cardiac Surgery Patients Without Atrial Fibrillation: A Meta-Analysis of Randomized and Propensity-Score Studies.
作者: Massimo Baudo.;Serge Sicouri.;Yoshiyuki Yamashita.;Mikiko Senzai.;Patrick M McCarthy.;Marc W Gerdisch.;Richard P Whitlock.;Basel Ramlawi.
来源: Circ Cardiovasc Interv. 2024年17卷10期e014296页
The role of left atrial appendage occlusion (LAAO) in patients without previous atrial fibrillation (AF) is not established. This meta-analysis was conducted on patients with normal sinus rhythm who underwent cardiac surgery, with and without concomitant LAAO, to evaluate its effect on the incidence of cerebrovascular accidents (CVAs).
22. Complete Versus Culprit-Only Revascularization in Older Patients With ST-Segment-Elevation Myocardial Infarction: An Individual Patient Meta-Analysis.
作者: Gianluca Campo.;Felix Böhm.;Thomas Engstrøm.;Pieter C Smits.;Islam Y Elgendy.;Gerry P McCann.;David A Wood.;Matteo Serenelli.;Stefan James.;Dan Eik Høfsten.;Bianca M Boxm-de Klerk.;Adrian Banning.;John A Cairns.;Rita Pavasini.;Goran Stankovic.;Petr Kala.;Henning Kelbæk.;Emanuele Barbato.;Ilija Srdanovic.;Mohamed Hamza.;Amerjeet S Banning.;Simone Biscaglia.;Shamir Mehta.
来源: Circulation. 2024年150卷19期1508-1516页
Complete revascularization is the standard treatment for patients with ST-segment-elevation myocardial infarction and multivessel disease. The FIRE trial (Functional Assessment in Elderly Myocardial Infarction Patients With Multivessel Disease) confirmed the benefit of complete revascularization in a population of older patients, but the follow-up is limited to 1 year. Therefore, the long-term benefit (>1 year) of this strategy in older patients is debated. To address this, an individual patient data meta-analysis was conducted in patients with ST-segment-elevation myocardial infarction ≥75 years of age enrolled in randomized clinical trials investigating complete versus culprit-only revascularization strategies.
23. Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
作者: Brendon L Neuen.;Robert A Fletcher.;Lauren Heath.;Adam Perkovic.;Muthiah Vaduganathan.;Sunil V Badve.;Katherine R Tuttle.;Richard Pratley.;Hertzel C Gerstein.;Vlado Perkovic.;Hiddo J L Heerspink.
来源: Circulation. 2024年150卷22期1781-1790页
GLP-1 (glucagon-like peptide-1) receptor agonists and SGLT2 (sodium-glucose cotransporter 2) inhibitors both improve cardiovascular and kidney outcomes in people with type 2 diabetes. We conducted a systematic review and meta-analysis to assess the effects of GLP-1 receptor agonists on clinical outcomes with and without SGLT2 inhibitors.
24. Procedural Outcomes With Femoral, Radial, Distal Radial, and Ulnar Access for Coronary Angiography: A Network Meta-Analysis.
作者: M Haisum Maqsood.;Celina M Yong.;Sunil V Rao.;Mauricio G Cohen.;Samir Pancholy.;Sripal Bangalore.
来源: Circ Cardiovasc Interv. 2024年17卷9期e014186页
Radial artery access for coronary angiography or percutaneous coronary intervention (PCI) reduces the risk of death, bleeding, and vascular complications and is preferred over femoral artery access, leading to a class 1 indication by clinical practice guidelines. However, alternate upper extremity access such as distal radial and ulnar access are not mentioned in the guidelines despite randomized trials. We aimed to evaluate procedural outcomes with femoral, radial, distal radial, and ulnar access sites in patients undergoing coronary angiography or PCI.
25. Role of Health Care Professionals in the Success of Blood Pressure Control Interventions in Patients With Hypertension: A Meta-Analysis.
作者: Katherine T Mills.;Samantha S O'Connell.;Meng Pan.;Katherine M Obst.;Hua He.;Jiang He.
来源: Circ Cardiovasc Qual Outcomes. 2024年17卷8期e010396页
Globally, only 13.8% of patients with hypertension have their blood pressure (BP) controlled. Trials testing interventions to overcome barriers to BP control have produced mixed results. Type of health care professional delivering the intervention may play an important role in intervention success. The goal of this meta-analysis is to determine which health care professionals are most effective at delivering BP reduction interventions.
26. Culprit-Only Revascularization, Single-Setting Complete Revascularization, and Staged Complete Revascularization in Acute Myocardial Infarction: Insights From a Mixed Treatment Comparison Meta-Analysis of Randomized Trials.
作者: Muhammad Haisum Maqsood.;Jacqueline E Tamis-Holland.;Sunil V Rao.;Gregg W Stone.;Sripal Bangalore.
来源: Circ Cardiovasc Interv. 2024年17卷7期e013737页
Complete revascularization improves cardiovascular outcomes compared with culprit-only revascularization in patients with acute myocardial infarction ([MI]; ST-segment-elevation MI or non-ST-segment-elevation MI) and multivessel coronary artery disease. However, the timing of complete revascularization (single-setting versus staged revascularization) is uncertain. The aim was to compare the outcomes of single-setting complete, staged complete, and culprit vessel-only revascularization in patients with acute MI and multivessel disease.
27. Meta-Analysis of Genome-Wide Association Studies Reveals Genetic Mechanisms of Supraventricular Arrhythmias.
作者: Lu-Chen Weng.;Shaan Khurshid.;Amelia Weber Hall.;Victor Nauffal.;Valerie N Morrill.;Yan V Sun.;Joel T Rämö.;Dominik Beer.;Simon Lee.;Girish Nadkarni.;Renee Johnson.;Laura Andreasen.;Anne Clayton.;Clive R Pullinger.;Zachary T Yoneda.;Daniel J Friedman.;Matthew C Hyman.;Renae L Judy.;Allan C Skanes.;Kate M Orland.;Paloma Jordà.;Timothy M Treu.;Matthew T Oetjens.;Rajesh Subbiah.;Jacob P Hartmann.;Heidi T May.;John P Kane.;Tariq Z Issa.;Navid A Nafissi.;Peter Leong-Sit.;Marie-Pierre Dubé.;Carolina Roselli.;Seung Hoan Choi.; .;Jean-Claude Tardif.;Habib R Khan.;Stacey Knight.;Jesper H Svendsen.;Bruce Walker.;Richard Karlsson Linnér.;J Michael Gaziano.;Rafik Tadros.;Diane Fatkin.;Daniel J Rader.;Svati H Shah.;Dan M Roden.;Gregory M Marcus.;Ruth J F Loos.;Scott M Damrauer.;Christopher M Haggerty.;Kelly Cho.;Aarno Palotie.;Morten S Olesen.;Lee L Eckhardt.;Jason D Roberts.;Michael J Cutler.;M Benjamin Shoemaker.;Peter W F Wilson.;Patrick T Ellinor.;Steven A Lubitz.
来源: Circ Genom Precis Med. 2024年17卷3期e004320页
Substantial data support a heritable basis for supraventricular tachycardias, but the genetic determinants and molecular mechanisms of these arrhythmias are poorly understood. We sought to identify genetic loci associated with atrioventricular nodal reentrant tachycardia (AVNRT) and atrioventricular accessory pathways or atrioventricular reciprocating tachycardia (AVAPs/AVRT).
28. Risks of Restrictive Versus Liberal Red Blood Cell Transfusion Strategies in Patients With Cardiovascular Disease: An Updated Meta-Analysis.
作者: Willard N Applefeld.;Verity J Ford.;Irene Cortes-Puch.;Jeffrey Wang.;Junfeng Sun.;Tracy C Shields.;Robert L Danner.;Peter Q Eichacker.;Michael A Solomon.;Harvey G Klein.;Charles Natanson.
来源: Circ Cardiovasc Qual Outcomes. 2024年17卷6期e010957页 29. Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
作者: Siddharth M Patel.;Yu Mi Kang.;KyungAh Im.;Brendon L Neuen.;Stefan D Anker.;Deepak L Bhatt.;Javed Butler.;David Z I Cherney.;Brian L Claggett.;Robert A Fletcher.;William G Herrington.;Silvio E Inzucchi.;Meg J Jardine.;Kenneth W Mahaffey.;Darren K McGuire.;John J V McMurray.;Bruce Neal.;Milton Packer.;Vlado Perkovic.;Scott D Solomon.;Natalie Staplin.;Muthiah Vaduganathan.;Christoph Wanner.;David C Wheeler.;Faiez Zannad.;Yujie Zhao.;Hiddo J L Heerspink.;Marc S Sabatine.;Stephen D Wiviott.
来源: Circulation. 2024年149卷23期1789-1801页
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) consistently improve heart failure and kidney-related outcomes; however, effects on major adverse cardiovascular events (MACE) across different patient populations are less clear.
30. Incremental Value of a Metabolic Risk Score for Heart Failure Mortality: A Population-Based Study.
作者: Jungnam Joo.;Joseph J Shearer.;Anna Wolska.;Alan T Remaley.;James D Otvos.;Margery A Connelly.;Maureen Sampson.;Suzette J Bielinski.;Nicholas B Larson.;Hoyoung Park.;Katherine M Conners.;Sarah Turecamo.;Véronique L Roger.
来源: Circ Genom Precis Med. 2024年17卷2期e004312页
Heart failure is heterogeneous syndrome with persistently high mortality. Nuclear magnetic resonance spectroscopy enables high-throughput metabolomics, suitable for precision phenotyping. We aimed to use targeted metabolomics to derive a metabolic risk score (MRS) that improved mortality risk stratification in heart failure.
31. Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main Disease With and Without Diabetes: Findings From a Pooled Analysis of 4 Randomized Clinical Trials.
作者: Prakriti Gaba.;Joseph F Sabik.;Sabina A Murphy.;Andrea Bellavia.;Patrick T O'Gara.;Peter K Smith.;Patrick W Serruys.;A Pieter Kappetein.;Seung-Jung Park.;Duk-Woo Park.;Evald H Christiansen.;Niels R Holm.;Per H Nielsen.;Marc S Sabatine.;Gregg W Stone.;Brian A Bergmark.
来源: Circulation. 2024年149卷17期1328-1338页
Diabetes may be associated with differential outcomes in patients undergoing left main coronary revascularization with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). The aim of this study was to investigate outcomes in patients with left main disease with and without diabetes randomized to PCI versus CABG.
33. Meta-Analysis of Normal Reference Values for Right and Left Ventricular Quantification by Cardiovascular Magnetic Resonance.
作者: Yang Zhan.;Matthias G Friedrich.;Nandini Dendukuri.;Yang Lu.;Michael Chetrit.;Ian Schiller.;Lawrence Joseph.;Jaime L Shaw.;Michael L Chuang.;Johannes H Riffel.;Warren J Manning.;Jonathan Afilalo.
来源: Circ Cardiovasc Imaging. 2024年17卷2期e016090页
Cardiovascular magnetic resonance (CMR) reference values are relied upon to accurately diagnose left ventricular (LV) and right ventricular (RV) pathologies. To date, reference values have been derived from modest sample sizes with limited patient diversity and attention to 1 but not both commonly used tracing techniques for papillary muscles and trabeculations. We sought to overcome these limitations by meta-analyzing normal reference values for CMR parameters stemming from multiple countries, vendors, analysts, and patient populations.
34. Coronary Angiography, Intravascular Ultrasound, and Optical Coherence Tomography for Guiding of Percutaneous Coronary Intervention: A Systematic Review and Network Meta-Analysis.
作者: Daniele Giacoppo.;Claudio Laudani.;Giovanni Occhipinti.;Marco Spagnolo.;Antonio Greco.;Carla Rochira.;Federica Agnello.;Davide Landolina.;Maria Sara Mauro.;Simone Finocchiaro.;Placido Maria Mazzone.;Nicola Ammirabile.;Antonino Imbesi.;Carmelo Raffo.;Sergio Buccheri.;Davide Capodanno.
来源: Circulation. 2024年149卷14期1065-1086页
Results from multiple randomized clinical trials comparing outcomes after intravascular ultrasound (IVUS)- and optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI) with invasive coronary angiography (ICA)-guided PCI as well as a pivotal trial comparing the 2 intravascular imaging (IVI) techniques have provided mixed results.
35. Efficacy and Safety of Non-Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation.
作者: Siddharth M Patel.;Eugene Braunwald.;Jan Steffel.;Giuseppe Boriani.;Michael G Palazzolo.;Elliott M Antman.;Erin A Bohula.;Anthony P Carnicelli.;Stuart J Connolly.;John W Eikelboom.;Baris Gencer.;Christopher B Granger.;David A Morrow.;Manesh R Patel.;Lars Wallentin.;Christian T Ruff.;Robert P Giugliano.; .
来源: Circulation. 2024年149卷12期932-943页
The efficacy and safety of non-vitamin-K antagonist oral anticoagulants (NOACs) across the spectrum of body mass index (BMI) and body weight (BW) remain uncertain.
36. Impact of GLA Variant Classification on the Estimated Prevalence of Fabry Disease: A Systematic Review and Meta-Analysis of Screening Studies.
作者: Emanuele Monda.;Gaetano Diana.;Francesca Graziani.;Marta Rubino.;Athanasios Bakalakos.;Ales Linhart.;Dominique P Germain.;Maurizio Scarpa.;Elena Biagini.;Maurizio Pieroni.;Perry Mark Elliott.;Giuseppe Limongelli.
来源: Circ Genom Precis Med. 2023年16卷6期e004252页
The diagnosis of Fabry disease (FD) has relevant implications related to the management. Thus, a clear assignment of GLA variant pathogenicity is crucial. This systematic review and meta-analysis aimed to investigate the prevalence of FD in high-risk populations and newborns and evaluate the impact of different GLA variant classifications on the estimated prevalence of FD.
37. Coronary Computed Tomography Angiography Versus Invasive Coronary Angiography in Stable Chest Pain: A Meta-Analysis of Randomized Controlled Trials.
作者: Marina F Machado.;Nicole Felix.;Pedro H C Melo.;Mateus M Gauza.;Pedro Calomeni.;Giuliano Generoso.;Sourabh Khatri.;Stephan Altmayer.;Ron Blankstein.;Marcio Sommer Bittencourt.;Rhanderson Cardoso.
来源: Circ Cardiovasc Imaging. 2023年16卷11期e015800页
The efficacy of coronary computed tomography angiography (CCTA) versus invasive coronary angiography (ICA) among patients with stable chest pain has been studied in several trials with conflicting results.
38. Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials.
作者: William F McIntyre.;Alexander P Benz.;Nina Becher.;Jeffrey S Healey.;Christopher B Granger.;Lena Rivard.;A John Camm.;Andreas Goette.;Antonia Zapf.;Marco Alings.;Stuart J Connolly.;Paulus Kirchhof.;Renato D Lopes.
来源: Circulation. 2024年149卷13期981-988页
Device-detected atrial fibrillation (also known as subclinical atrial fibrillation or atrial high-rate episodes) is a common finding in patients with an implanted cardiac rhythm device and is associated with an increased risk of ischemic stroke. Whether oral anticoagulation is effective and safe in this patient population is unclear.
39. Major Facilitator Superfamily Domain Containing 5 Inhibition Reduces Lipoprotein(a) Uptake and Calcification in Valvular Heart Disease.
作者: Maximillian A Rogers.;Francesca Bartoli-Leonard.;Kang H Zheng.;Aeron M Small.;Hao Yu Chen.;Cassandra L Clift.;Takaharu Asano.;Shiori Kuraoka.;Mark C Blaser.;Katelyn A Perez.;Pradeep Natarajan.;Calvin Yeang.;Erik S G Stroes.;Sotirios Tsimikas.;James C Engert.;George Thanassoulis.;Christopher J O'Donnell.;Masanori Aikawa.;Sasha A Singh.;Elena Aikawa.
来源: Circulation. 2024年149卷5期391-401页
High circulating levels of Lp(a) (lipoprotein[a]) increase the risk of atherosclerosis and calcific aortic valve disease, affecting millions of patients worldwide. Although atherosclerosis is commonly treated with low-density lipoprotein-targeting therapies, these do not reduce Lp(a) or risk of calcific aortic valve disease, which has no available drug therapies. Targeting Lp(a) production and catabolism may provide therapeutic benefit, but little is known about Lp(a) cellular uptake.
40. Meta-Analysis of Penetrance and Systematic Review on Transition to Disease in Genetic Hypertrophic Cardiomyopathy.
作者: Constantin-Cristian Topriceanu.;Alexandre C Pereira.;James C Moon.;Gabriella Captur.;Carolyn Y Ho.
来源: Circulation. 2024年149卷2期107-123页
Hypertrophic cardiomyopathy (HCM) is characterized by unexplained left ventricular hypertrophy and is classically caused by pathogenic or likely pathogenic variants (P/LP) in genes encoding sarcomere proteins. Not all subclinical variant carriers will manifest clinically overt disease because penetrance (proportion of sarcomere or sarcomere-related P/LP variant carriers who develop disease) is variable, age dependent, and not reliably predicted.
|